Abstract / Description of output
The QT interval is an electrocardiographic measure representing the sum of ventricular depolarization and repolarization, estimated by QRS duration and JT interval, respectively. QT interval abnormalities are associated with potentially fatal ventricular arrhythmia. Using genome-wide multi-ancestry analyses (>250,000 individuals) we identify 177, 156 and 121 independent loci for QT, JT and QRS, respectively, including a male-specific X-chromosome locus. Using gene-based rare-variant methods, we identify associations with Mendelian disease genes. Enrichments are observed in established pathways for QT and JT, and previously unreported genes indicated in insulin-receptor signalling and cardiac energy metabolism. In contrast for QRS, connective tissue components and processes for cell growth and extracellular matrix interactions are significantly enriched. We demonstrate polygenic risk score associations with atrial fibrillation, conduction disease and sudden cardiac death. Prioritization of druggable genes highlight potential therapeutic targets for arrhythmia. Together, these results substantially advance our understanding of the genetic architecture of ventricular depolarization and repolarization.
Original language | English |
---|---|
Article number | 5144 |
Journal | Nature Communications |
Volume | 13 |
Issue number | 1 |
DOIs | |
Publication status | Published - 1 Sept 2022 |
Keywords / Materials (for Non-textual outputs)
- Arrhythmias, Cardiac/genetics
- Death, Sudden, Cardiac
- Electrocardiography/methods
- Genetic Testing
- Humans
- Male
Access to Document
- Genetic analyses of the electrocardiographic QT interval and its components identify additional loci and pathwaysFinal published version, 3.68 MBLicence: Creative Commons: Attribution (CC-BY)
Fingerprint
Dive into the research topics of 'Genetic analyses of the electrocardiographic QT interval and its components identify additional loci and pathways'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Nature Communications, Vol. 13, No. 1, 5144, 01.09.2022.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Genetic analyses of the electrocardiographic QT interval and its components identify additional loci and pathways
AU - Young, William J.
AU - Lahrouchi, Najim
AU - Isaacs, Aaron
AU - Duong, Thuyvy
AU - Foco, Luisa
AU - Ahmed, Farah
AU - Brody, Jennifer A.
AU - Salman, Reem
AU - Noordam, Raymond
AU - Benjamins, Jan-walter
AU - Haessler, Jeffrey
AU - Lyytikäinen, Leo-pekka
AU - Repetto, Linda
AU - Concas, Maria Pina
AU - Van Den Berg, Marten E.
AU - Weiss, Stefan
AU - Baldassari, Antoine R.
AU - Bartz, Traci M.
AU - Cook, James P.
AU - Evans, Daniel S.
AU - Freudling, Rebecca
AU - Hines, Oliver
AU - Isaksen, Jonas L.
AU - Lin, Honghuang
AU - Mei, Hao
AU - Moscati, Arden
AU - Müller-nurasyid, Martina
AU - Nursyifa, Casia
AU - Qian, Yong
AU - Richmond, Anne
AU - Roselli, Carolina
AU - Ryan, Kathleen A.
AU - Tarazona-santos, Eduardo
AU - Thériault, Sébastien
AU - Van Duijvenboden, Stefan
AU - Warren, Helen R.
AU - Yao, Jie
AU - Raza, Dania
AU - Aeschbacher, Stefanie
AU - Ahlberg, Gustav
AU - Alonso, Alvaro
AU - Andreasen, Laura
AU - Bis, Joshua C.
AU - Boerwinkle, Eric
AU - Campbell, Archie
AU - Catamo, Eulalia
AU - Cocca, Massimiliano
AU - Cutler, Michael J.
AU - Darbar, Dawood
AU - De Grandi, Alessandro
AU - De Luca, Antonio
AU - Ding, Jun
AU - Ellervik, Christina
AU - Ellinor, Patrick T.
AU - Felix, Stephan B.
AU - Froguel, Philippe
AU - Fuchsberger, Christian
AU - Gögele, Martin
AU - Graff, Claus
AU - Graff, Mariaelisa
AU - Guo, Xiuqing
AU - Hansen, Torben
AU - Heckbert, Susan R.
AU - Huang, Paul L.
AU - Huikuri, Heikki V.
AU - Hutri-kähönen, Nina
AU - Ikram, M. Arfan
AU - Jackson, Rebecca D.
AU - Junttila, Juhani
AU - Kavousi, Maryam
AU - Kors, Jan A.
AU - Leal, Thiago P.
AU - Lemaitre, Rozenn N.
AU - Lin, Henry J.
AU - Lind, Lars
AU - Linneberg, Allan
AU - Liu, Simin
AU - Macfarlane, Peter W.
AU - Mangino, Massimo
AU - Meitinger, Thomas
AU - Mezzavilla, Massimo
AU - Mishra, Pashupati P.
AU - Mitchell, Rebecca N.
AU - Mononen, Nina
AU - Montasser, May E.
AU - Morrison, Alanna C.
AU - Nauck, Matthias
AU - Nauffal, Victor
AU - Navarro, Pau
AU - Nikus, Kjell
AU - Pare, Guillaume
AU - Patton, Kristen K.
AU - Pelliccione, Giulia
AU - Pittman, Alan
AU - Porteous, David J.
AU - Pramstaller, Peter P.
AU - Preuss, Michael H.
AU - Raitakari, Olli T.
AU - Reiner, Alexander P.
AU - Ribeiro, Antonio Luiz P.
AU - Rice, Kenneth M.
AU - Risch, Lorenz
AU - Schlessinger, David
AU - Schotten, Ulrich
AU - Schurmann, Claudia
AU - Shen, Xia
AU - Shoemaker, M. Benjamin
AU - Sinagra, Gianfranco
AU - Sinner, Moritz F.
AU - Soliman, Elsayed Z.
AU - Stoll, Monika
AU - Strauch, Konstantin
AU - Tarasov, Kirill
AU - Taylor, Kent D.
AU - Tinker, Andrew
AU - Trompet, Stella
AU - Uitterlinden, André
AU - Völker, Uwe
AU - Völzke, Henry
AU - Waldenberger, Melanie
AU - Weng, Lu-chen
AU - Whitsel, Eric A.
AU - Wilson, James G.
AU - Avery, Christy L.
AU - Conen, David
AU - Correa, Adolfo
AU - Cucca, Francesco
AU - Dörr, Marcus
AU - Gharib, Sina A.
AU - Girotto, Giorgia
AU - Grarup, Niels
AU - Hayward, Caroline
AU - Jamshidi, Yalda
AU - Järvelin, Marjo-riitta
AU - Jukema, J. Wouter
AU - Kääb, Stefan
AU - Kähönen, Mika
AU - Kanters, Jørgen K.
AU - Kooperberg, Charles
AU - Lehtimäki, Terho
AU - Lima-costa, Maria Fernanda
AU - Liu, Yongmei
AU - Loos, Ruth J. F.
AU - Lubitz, Steven A.
AU - Mook-kanamori, Dennis O.
AU - Morris, Andrew P.
AU - O’connell, Jeffrey R.
AU - Olesen, Morten Salling
AU - Orini, Michele
AU - Padmanabhan, Sandosh
AU - Pattaro, Cristian
AU - Peters, Annette
AU - Psaty, Bruce M.
AU - Rotter, Jerome I.
AU - Stricker, Bruno
AU - Van Der Harst, Pim
AU - Van Duijn, Cornelia M.
AU - Verweij, Niek
AU - Wilson, James G.
AU - Arking, Dan E.
AU - Ramirez, Julia
AU - Lambiase, Pier D.
AU - Sotoodehnia, Nona
AU - Mifsud, Borbala
AU - Newton-cheh, Christopher
AU - Munroe, Patricia B.
N1 - Funding Information: M.J.C. has consulted for Biosense Webster and Janssen Scientific. S.A.L. receives sponsored research support from Bristol Myers Squibb/Pfizer, Bayer AG, Boehringer Ingelheim, Fitbit, and IBM, and has consulted for Bristol Myers Squibb/Pfizer, Bayer AG, and Blackstone Life Sciences. P.T.E. has received grant funding from Bayer AG and served on advisory boards or consulted for Bayer AG, Quest Diagnostics, MyoKardia and Novartis. B.M.P. serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. D.O.M.-K. is a part time research consultant at Metabolon, Inc. D.C has received speaker fees from BMS/Pfizer and consultation fees from Roche Diagnostics. U.S received consultancy fees or honoraria from Università della Svizzera Italiana (USI, Switzerland), Roche Diagnostics (Switzerland), EP Solutions Inc. (Switzerland), Johnson & Johnson Medical Limited, (United Kingdom), Bayer Healthcare (Germany). U.S is co-founder and shareholder of YourRhythmics BV, a spin-off company of the University Maastricht. L.-C.W receives sponsored research support from IBM to the Broad Institute. The remaining authors declare no competing interests. Funding Information: All study acknowledgements can be found in Supplementary Note 3 , and study funding information in Supplementary Note 4. William J Young was supported by an MRC grant MR/R017468/1. Alvaro Alonso is supported by an NHLBI award K24HL148521. Antonio Luiz P Ribeiro is supported in part by CNPq (310679/2016-8 and 465518/2014-1) and by FAPEMIG (PPM-00428-17 and RED-00081-16). Eduardo Tarazona-Santos, Maria Fernanda Lima-Costa and Thiago P Leal are supported by Brazilian Conselho Nacional de Desenvolvimento Científico e Tecnologico (CNPq). Eduardo Tarazona-Santos and Maria Fernanda Lima-Costa are also supported by the Brazilian Ministry of Health (DECIT/MS, EPIGEN-Brazil Project), Brazilian Ministry of Science and Technology (Financiadora de Estudos e Projetos (FINEP) and Fundação de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG). Ruth Loos is supported by the National Institutes of Health (R01DK110113; R01DK107786; R01HL142302; R01DK124097). Michael J Cutler is supported by funding from the Dell Loy Hansen Heart Foundation. M.Benjamin Shoemaker is supported by grant NIHK23HL127704. Rozenn Lemaitre reports funding from grant: AHA 19SFRN34830063. Steven A Lubitz is supported by NIH grant 1R01HL139731 and American Heart Association 18SFRN34250007. Patrick T Ellinor was supported by grants from Bayer AG, the Foundation Leducq (14CVD01), the NIH (1RO1HL092577, R01HL128914, K24HL105780), and the American Heart Association (18SFRN34110082). Lu-Chen Weng was supported by National Institutes of Health (NIH) grant 1R01HL139731 and American Heart Association (AHA) grant 18SFRN34110082. Victor Nauffal is funded by a T32 training grant from the National Institutes of Health (5T32HL007604-35). Nona Sotoodehnia is supported by grants AHA19SFRN348300063, R01HL141989, Medic One Foundation, Laughlin Family. Ulrich Schotten received funding from the Netherlands Heart Foundation (CVON2014-09, RACE V Reappraisal of Atrial Fibrillation: Interaction between hypercoagulability, Electrical remodelling, and Vascular Destabilization in the Progression of AF), the European Union (ITN Network Personalize AF: Personalized Therapies for Atrial Fibrillation: a translational network, grant number 860974; MAESTRIA: Machine Learning Artificial Intelligence Early Detection Stroke Atrial Fibrillation, grant number 965286). Sébastien Thériault is supported by a Junior 1 Clinical Research Scholar award from the Fonds de Recherche du Québec-Santé (FRQS). Jonas L Isaksen is supported by CACHET. Caroline Hayward is supported by an MRC University Unit Programme Grant MC_UU_00007/10 (QTL in Health and Disease). Christy Avery and Antoine Baldassari were supported by NIH grants R01HL142825, and U01HG007416. Dawood Darbar was supported by NIH grants R01HL138737 and T32HL139439. Daniel S Evans is supported by NIH grant U24AG051129. Niels Grarup is supported by the Novo Nordisk Foundation (Grant number NNF18CC0034900). James G. Wilson is supported by U54GM115428 from the National Institute of General Medical Sciences. Hao Mei is also supported by the CHARGE infrastructure grant (HL105756). Dennis Mook-Kanamori is supported by Dutch Science Organization (ZonMW-VENI Grant 916.14.023). May E Montasser receives funding from Regeneron Pharmaceutical unrelated to this work. James F Wilson and Pau Navarro acknowledge support from the MRC Human Genetics Unit programme grant, “Quantitative traits in health and disease” (U. MC_UU_00007/10). Linda Repetto is funded by a University of Edinburgh studentship. Xia Shen was in receipt of a Starting Grant (2017-02543) from the Swedish Research Council (Vetenskaprådet). Lars Lind is funded by Uppsala University Hospital, Uppsala, Sweden. Niek Verweij was supported by NWO VENI (016.186.125). Jan-Walter Benjamins is funded by the Research Project CVON-AI (2018B017) financed by the PPP Allowance made available by Top Sector Life Sciences & Health to the Dutch Heart Foundation to stimulate public-private partnerships. J.Wouter Jukema is an Established Clinical Investigator of the Netherlands Heart Foundation (grant 2001 D 032). Oliver Hines is supported by a Medical Research Council DTP Studentship. Massimo Mangino is supported by the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust in partnership with King’s College London. Patricia B Munroe, Pier D Lambiase, Andrew Tinker and Michele Orini were supported by Medical Research Council grant MR/N025083/1. Julia Ramirez is funded by European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No.786833. Pier D Lambiase is supported by UCL/UCLH Biomedicine NIHR, Barts Heart Centre Biomedical Research Centre. Patricia B Munroe, Pier D Lambiase, Andrew Tinker and Helen Warren acknowledge the NIHR Cardiovascular Biomedical Centre at Barts and The London, Queen Mary University of London. Christopher Newton-Cheh acknowledges support from the National Institutes of Health (R01HL143070). The authors also wish to acknowledge the CHARGE infrastructure grant (HL105756). Publisher Copyright: © 2022, The Author(s).
PY - 2022/9/1
Y1 - 2022/9/1
N2 - The QT interval is an electrocardiographic measure representing the sum of ventricular depolarization and repolarization, estimated by QRS duration and JT interval, respectively. QT interval abnormalities are associated with potentially fatal ventricular arrhythmia. Using genome-wide multi-ancestry analyses (>250,000 individuals) we identify 177, 156 and 121 independent loci for QT, JT and QRS, respectively, including a male-specific X-chromosome locus. Using gene-based rare-variant methods, we identify associations with Mendelian disease genes. Enrichments are observed in established pathways for QT and JT, and previously unreported genes indicated in insulin-receptor signalling and cardiac energy metabolism. In contrast for QRS, connective tissue components and processes for cell growth and extracellular matrix interactions are significantly enriched. We demonstrate polygenic risk score associations with atrial fibrillation, conduction disease and sudden cardiac death. Prioritization of druggable genes highlight potential therapeutic targets for arrhythmia. Together, these results substantially advance our understanding of the genetic architecture of ventricular depolarization and repolarization.
AB - The QT interval is an electrocardiographic measure representing the sum of ventricular depolarization and repolarization, estimated by QRS duration and JT interval, respectively. QT interval abnormalities are associated with potentially fatal ventricular arrhythmia. Using genome-wide multi-ancestry analyses (>250,000 individuals) we identify 177, 156 and 121 independent loci for QT, JT and QRS, respectively, including a male-specific X-chromosome locus. Using gene-based rare-variant methods, we identify associations with Mendelian disease genes. Enrichments are observed in established pathways for QT and JT, and previously unreported genes indicated in insulin-receptor signalling and cardiac energy metabolism. In contrast for QRS, connective tissue components and processes for cell growth and extracellular matrix interactions are significantly enriched. We demonstrate polygenic risk score associations with atrial fibrillation, conduction disease and sudden cardiac death. Prioritization of druggable genes highlight potential therapeutic targets for arrhythmia. Together, these results substantially advance our understanding of the genetic architecture of ventricular depolarization and repolarization.
KW - Arrhythmias, Cardiac/genetics
KW - Death, Sudden, Cardiac
KW - Electrocardiography/methods
KW - Genetic Testing
KW - Humans
KW - Male
U2 - 10.1038/s41467-022-32821-z
DO - 10.1038/s41467-022-32821-z
M3 - Article
C2 - 36050321
SN - 2041-1723
VL - 13
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 5144
ER -